Clinical Trials Logo

Heart Failure clinical trials

View clinical trials related to Heart Failure.

Filter by:

NCT ID: NCT03490994 Not yet recruiting - Acute Heart Failure Clinical Trials

Rivaroxaban Once Daily Versus Dose-adjusted Vitamin K Antagonist on the Biomarkers in Acute Decompensated Heart Failure and Atrial Fibrillation (ROAD HF-AF)

Start date: April 2018
Phase: Phase 4
Study type: Interventional

Vitamin K antagonists (VKAs) are used to reduce the risk of stroke (cerebral vascular dysfunction) in AF patients. However, VKAs interact with drugs/food and the drug level is influenced by worsening of renal function, liver congestion or hemodynamic alterations in acute decompensated heart failure (ADHF). New oral anticoagulants (rivaroxaban, apixaban, dabigatran) are alternatives to VKA, such as warfarin. In post hoc analysis of ROCKET AF trial, 63.7% patients had HF and treatment-related outcomes were similar in patients with and without HF (Circulation HF. 2013; 6:740-7). So rivaroxaban 20 mg daily (or 15 mg daily in patients with creatinine clearance 30-49 mL/min) was safe in nonvalvular AF patients with HF. However, the clinical effect and safety of rivaroxaban were largely unknown in acute decompensated heart failure (ADHF) patients with atrial fibrillation (AF). ROAD HF-AF is the exploratory study to assess the change of surrogate markers (hsTn, d-dimer) when treated with rivaroxaban vs. warfarin and to strengthen the basis for future biomarker-based therapy in ADHF patients

NCT ID: NCT03489005 Recruiting - Heart Failure Clinical Trials

Effect of BIA 5 1058 on Cardiac Repolarization

Start date: April 2018
Phase: Phase 1
Study type: Interventional

The purpose is to evaluate the effect of single therapeutic (400 mg) and supratherapeutic (1200 mg) doses of BIA 5-1058 on the time-matched change from baseline in placebo-adjusted interval corrected (QT) for heart rate (HR)

NCT ID: NCT03488979 Completed - Clinical trials for Acute Decompensated Heart Failure

Effect of Providing Education and Patient's Inferior Vena Cava Ultrasound Images on Adherence to a Heart Failure Regimen

Start date: March 16, 2015
Phase:
Study type: Observational

Heart failure is a common, costly, and disabling condition characterized by recurrent exacerbations. Episodes of acute decompensated heart failure (ADHF) account for the largest proportion of admissions and 30-day readmissions to US hospitals. Medication nonadherence and dietary/fluid nonadherence have been associated with re-admissions. Hand-carried ultrasound (HCU) devices are portable, relatively inexpensive, and can augment the physical exam in the assessment of volume status. Dilated Inferior Vena Cava (IVC) with poor collapsibility correlates with elevated central venous pressure, which may be correlated with earlier readmission for ADHF. Study design to measure maximum IVC diameter (IVC max) in mm and the degree of IVC collapsibility with inspiration on qualitative assessment in approximately 100 patients admitted with ADHF. The co-investigator will share the IVC images and interpretation with educational intervention group patients in real time; IVC images and interpretation will not be shared with control group patients. Study team will assess whether sharing these IVC measurements correlates with greater adherence to heart failure self-management after discharge, as measured by the administration of the Medical Outcomes Study Specific Adherence Scale, modified to a 3-item version relevant for patients with heart failure (MOSSAS-3HF) at 4 weeks after discharge. Study team will also assess for any difference in 30-day readmission rates for intervention vs. control group patients.

NCT ID: NCT03485092 Recruiting - Heart Failure Clinical Trials

Studies of Empagliflozin and Its Cardiovascular, Renal and Metabolic Effects

SUGAR
Start date: March 16, 2018
Phase: Phase 4
Study type: Interventional

The investigators hypothesise that empagliflozin 10mg daily will have haemodynamic, cardiac, and renal benefits compared to placebo over 36 weeks in heart failure patients with type 2 diabetes, leading to measurable improvements in clinical measures of cardiac structure and function (LVESVI, and LV strain) as well as renal blood flow.

NCT ID: NCT03484780 Recruiting - Heart Failure Clinical Trials

VisONE Heart Failure Study: Pilot

Start date: April 2018
Phase: N/A
Study type: Interventional

This is a pilot for evaluating the benefits and risks of chronically delivering Asymptomatic Diaphragmatic Stimulation in medical refractory heart failure patients using the VisONEā„¢ implantable system for 12 months.

NCT ID: NCT03484286 Recruiting - Heart Failure Clinical Trials

Selfcare Management Intervention in Heart Failure

SMART-HF
Start date: April 3, 2018
Phase: Phase 2
Study type: Interventional

A novel tool for self-care enhancement for heart failure (HF) patients has been developed. In this randomized controlled trial, patients will be randomized 1:1 to either receive the home-based tool (OPTILOGG) or standard care. The intervention will go on for 8 months, and outcomes are self-care, quality of life, cardiovascular events (including emergency visits, admissions and number of in-hospital days).

NCT ID: NCT03480633 Recruiting - Clinical trials for Heart Failure With Reduced Ejection Fraction

Biorepository Studying the Relationship Between Biomarkers and Heart Failure

PREFER-HF
Start date: April 7, 2016
Phase:
Study type: Observational [Patient Registry]

This study aims to prospectively evaluate the relationship between serial measurement of several biomarkers, such as insulin-like growth factor binding protein 7 (IGFBP7), bone morphogenic protein 1 (BMP1), and carboxyterminal propeptide of type-I procollagen (PICP), and echocardiographic features of diastolic dysfunction in three groups, including patients with heart failure with preserved ejection fraction (HFpEF), heart failure with reduced ejection fraction (HFrEF), and patients without a history of heart failure (HF). The relationship between these novel biomarkers and one year major cardiovascular adverse events will also be evaluated.

NCT ID: NCT03479424 Not yet recruiting - Clinical trials for NYHA Class II-IV Heart Failure

Home Outpatient Monitoring and Engagement to Predict HF Exacerbation

Home Predict
Start date: April 2018
Phase:
Study type: Observational

The HOME PREDICT HF study looks at new ways to predict hospitalizations for heart failure. We will use a set of devices at home and surveys to collect information about patient's health. This study uses the Eureka app, a new study app developed by the University of California, San Francisco. The study is designed to happen remotely, using this application on a patient's smartphone, so that is as convenient as possible to participate.

NCT ID: NCT03478267 Not yet recruiting - Clinical trials for Fetal Heart Failure (Disorder)

The Relationship Between Fetal Baseline Heart-rate and the Level of Acetyl-choline Esterase in Fetal Blood

Start date: July 1, 2018
Phase:
Study type: Observational [Patient Registry]

Pregnant women between 32-41 weeks` gestation designated for either vaginal birth or cesarean section will be recruited for the study. Data regarding maternal resting heart rate and fetal baseline heart rate as depicted on the monitor will be collected. A blood sample will be acquired from the parturient and the umbilical cord as well as a sample from the placenta will be obtained. Levels of Acetyl Choline Esterase (AChE) will be determined from all aforementioned samples. Statistical correlation between fetal baseline heart rate and fetal and maternal AChE levels will be assessed.

NCT ID: NCT03476785 Recruiting - Clinical trials for Heart Failure, Diastolic

Prevention of Cardiovascular Stiffening With Aging and Hypertensive Heart Disease

LVH
Start date: June 1, 2015
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether vigorous exercise training 4-5 days/week for one year in sedentary middle aged (ages 40-64) individuals at high risk for future development of heart failure will improve cardiac and vascular compliance to a degree equivalent to life-long exercisers and the sedentary young. To date, no effective therapy for heart failure with preserved ejection fraction (HFpEF) has been found; therefore prevention is critical and discovering novel treatment strategies is essential. Exercise training if implemented in high risk patients may improve diastolic function and cardiac-vascular interactions, preventing further progression to overt heart failure.